Clinical Trial Update: Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 efficacy study of imatinib mesylate for Philadelphia chromosome-positive acute lymphoblastic leukemia has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Philadelphia Chromosome Positive Acute Lymphocytic Leukemia | Phase 2 | Status: COMPLETED